iPSC technology-Powerful hand for disease modeling and therapeutic screen

Changsung Kim

Research output: Contribution to journalShort survey

14 Citations (Scopus)

Abstract

Cardiovascular and neurodegenerative diseases are major health threats in many developed countries. Recently, target tissues derived from human embryonic stem (hES) cells and induced pluripotent stem cells (iPSCs), such as cardiomyocytes (CMs) or neurons, have been actively mobilized for drug screening. Knowledge of drug toxicity and efficacy obtained using stem cell-derived tissues could parallel that obtained from human trials. Furthermore, iPSC disease models could be advantageous in the development of personalized medicine in various parts of disease sectors. To obtain the maximum benefit from iPSCs in disease modeling, researchers are now focusing on aging, maturation, and metabolism to recapitulate the pathological features seen in patients. Compared to pediatric disease modeling, adult-onset disease modeling with iPSCs requires proper maturation for full manifestation of pathological features. Herein, the success of iPSC technology, focusing on patient-specific drug treatment, maturation-based disease modeling, and alternative approaches to compensate for the current limitations of patient iPSC modeling, will be further discussed.

Original languageEnglish (US)
Pages (from-to)256-265
Number of pages10
JournalBMB Reports
Volume48
Issue number5
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Induced Pluripotent Stem Cells
Stem cells
Hand
Technology
Therapeutics
Precision Medicine
Preclinical Drug Evaluations
Neurodegenerative diseases
Tissue
Drug-Related Side Effects and Adverse Reactions
Drug therapy
Developed Countries
Cardiac Myocytes
Neurodegenerative Diseases
Pediatrics
Cardiovascular Diseases
Stem Cells
Research Personnel
Metabolism
Pharmaceutical Preparations

Keywords

  • Disease modeling
  • Drug screen
  • IPSC
  • Patient specific therapy
  • Stem cell

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

iPSC technology-Powerful hand for disease modeling and therapeutic screen. / Kim, Changsung.

In: BMB Reports, Vol. 48, No. 5, 2015, p. 256-265.

Research output: Contribution to journalShort survey

Kim, Changsung. / iPSC technology-Powerful hand for disease modeling and therapeutic screen. In: BMB Reports. 2015 ; Vol. 48, No. 5. pp. 256-265.
@article{101fa71d8c4443cea3ff802d974a5a96,
title = "iPSC technology-Powerful hand for disease modeling and therapeutic screen",
abstract = "Cardiovascular and neurodegenerative diseases are major health threats in many developed countries. Recently, target tissues derived from human embryonic stem (hES) cells and induced pluripotent stem cells (iPSCs), such as cardiomyocytes (CMs) or neurons, have been actively mobilized for drug screening. Knowledge of drug toxicity and efficacy obtained using stem cell-derived tissues could parallel that obtained from human trials. Furthermore, iPSC disease models could be advantageous in the development of personalized medicine in various parts of disease sectors. To obtain the maximum benefit from iPSCs in disease modeling, researchers are now focusing on aging, maturation, and metabolism to recapitulate the pathological features seen in patients. Compared to pediatric disease modeling, adult-onset disease modeling with iPSCs requires proper maturation for full manifestation of pathological features. Herein, the success of iPSC technology, focusing on patient-specific drug treatment, maturation-based disease modeling, and alternative approaches to compensate for the current limitations of patient iPSC modeling, will be further discussed.",
keywords = "Disease modeling, Drug screen, IPSC, Patient specific therapy, Stem cell",
author = "Changsung Kim",
year = "2015",
doi = "10.5483/BMBRep.2015.48.5.100",
language = "English (US)",
volume = "48",
pages = "256--265",
journal = "BMB Reports",
issn = "1976-6696",
publisher = "The Biochemical Society of the Republic of Korea",
number = "5",

}

TY - JOUR

T1 - iPSC technology-Powerful hand for disease modeling and therapeutic screen

AU - Kim, Changsung

PY - 2015

Y1 - 2015

N2 - Cardiovascular and neurodegenerative diseases are major health threats in many developed countries. Recently, target tissues derived from human embryonic stem (hES) cells and induced pluripotent stem cells (iPSCs), such as cardiomyocytes (CMs) or neurons, have been actively mobilized for drug screening. Knowledge of drug toxicity and efficacy obtained using stem cell-derived tissues could parallel that obtained from human trials. Furthermore, iPSC disease models could be advantageous in the development of personalized medicine in various parts of disease sectors. To obtain the maximum benefit from iPSCs in disease modeling, researchers are now focusing on aging, maturation, and metabolism to recapitulate the pathological features seen in patients. Compared to pediatric disease modeling, adult-onset disease modeling with iPSCs requires proper maturation for full manifestation of pathological features. Herein, the success of iPSC technology, focusing on patient-specific drug treatment, maturation-based disease modeling, and alternative approaches to compensate for the current limitations of patient iPSC modeling, will be further discussed.

AB - Cardiovascular and neurodegenerative diseases are major health threats in many developed countries. Recently, target tissues derived from human embryonic stem (hES) cells and induced pluripotent stem cells (iPSCs), such as cardiomyocytes (CMs) or neurons, have been actively mobilized for drug screening. Knowledge of drug toxicity and efficacy obtained using stem cell-derived tissues could parallel that obtained from human trials. Furthermore, iPSC disease models could be advantageous in the development of personalized medicine in various parts of disease sectors. To obtain the maximum benefit from iPSCs in disease modeling, researchers are now focusing on aging, maturation, and metabolism to recapitulate the pathological features seen in patients. Compared to pediatric disease modeling, adult-onset disease modeling with iPSCs requires proper maturation for full manifestation of pathological features. Herein, the success of iPSC technology, focusing on patient-specific drug treatment, maturation-based disease modeling, and alternative approaches to compensate for the current limitations of patient iPSC modeling, will be further discussed.

KW - Disease modeling

KW - Drug screen

KW - IPSC

KW - Patient specific therapy

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=84930923281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930923281&partnerID=8YFLogxK

U2 - 10.5483/BMBRep.2015.48.5.100

DO - 10.5483/BMBRep.2015.48.5.100

M3 - Short survey

C2 - 25104399

AN - SCOPUS:84930923281

VL - 48

SP - 256

EP - 265

JO - BMB Reports

JF - BMB Reports

SN - 1976-6696

IS - 5

ER -